Research Information System
ACS OMEGA, vol.000, no.000, 2025 (SCI-Expanded, Scopus)
The present study describes the design, synthesis, and characterization of two novel palladium(II) complexes incorporating phosphine and benzimidazole ligands, followed by a comprehensive evaluation of their antioxidant and antiangiogenic properties. The complexes were fully characterized using spectroscopic and analytical methods. Antioxidant capacity was investigated through a multiassay approach, including ferrous ion- chelating activity, reducing power, and ABTS•+ radical cation decolorization. Antiangiogenic activity was evaluated in vivo using the chick chorioallantoic membrane (CAM) assay. Palladium complex 1 exhibited the strongest ferrous ion-chelating ability (71.91% inhibition) and the highest ABTS•+ scavenging activity (49.79%), while Palladium complex 2 demonstrated superior reducing power (EC50 = 1.06 mg/mL). Both complexes showed strong antiangiogenic effects, with Palladium complex 1 achieving an average inhibition score of 0.90-comparable to the positive control (±)-thalidomideand without observable irritation or toxicity. These results indicate that both complexes possess potent biological activities; however, the overall antioxidant and antiangiogenic profile of Palladium complex 1 suggests it may be particularly promising as a redox-modulating agent targeting oxidative stress−induced angiogenesis. To the best of our knowledge, this is the first report of palladium−phosphine−benzimidazole complexes demonstrating such dual activity, highlighting their potential as multifunctional candidates in cancer-related therapeutic research.